anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention provides a process for preparing a pharmaceutical composition comprising N-[(1-<n>butyl-4-piperidinyl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carbixamide (pharmaceutical composition) (piboserod) or a pharmaceutically acceptable salt thereof in combination with one or more pharmaceutically acceptable excipients, the process comprising forming part or all of the (pharmaceutical composition) or the salt thereof into granules by a dry granulation process. The process is preferably a roller compaction process, preferably followed by milling to a suitable particle size. The granules are usually of increased particle size and/or compacted compared to the SB 207266 or the salt thereof. Preferably, the (pharmaceutical composition) or the salt thereof is present in the composition and/or in the granules in at least 4 weight % and/or up to 60 weight % by weight of the composition and/or by weight of the granules respectively. An intragranular lubricant, filler (e.g. CaHPO4), and/or compression aid (e.g. microcrystalline cellulose) are usually used. The invention also provides a pharmaceutical composition obtainable by the dry granulation process and/or which has been prepared by the dry granulation process.
Induction camrelizumab therapy at least one cycle (every 3 weeks) followed by definitive concurrent chemoradiotherapy. After 4\~6 weeks of the completion of radiotherapy, adjuvant camrelizumab therapy will begin every 3 weeks for 16 cycles (1 year) or continue until progression or unacceptable toxicity.
The present invention relates to stilbene and quinone compounds related to combretastatin A-4 and their use as anticancer compounds and prodrugs. The compounds include those with an alkyl group on the double bond of cis or trans-stilbenes, compounds with one or more (and preferably 2 or 3) alkyl group substituents on the stilbene A ring, compounds with an alkoxy group other than methoxy at position 3, 4, and/or 5 of the stilbene A ring, compounds (or prodrugs) in which BOC amino acid esters are formed with the phenolic hydroxyl at the 3-position of the B ring and compounds (or prodrugs) based on a benzoquinone B ring. The present invention further relates to the photochemical reactions of stilbene compounds, either the above compounds disclosed for the first time herein or compounds based on prior art stilbenes.  These reactions include the photochemical release of an active form of the compound from a prodrug conjugate and the photochemical isomerisation of the compounds, especially from a trans to cis form of compounds. The reactions can be used alone or in combination to convert inactive or comparatively less active forms of the compounds to more active forms,thereby allowing the compounds to be selectively targeted, e.g. activating them at the site of a tumour.
The invention relates to a new application of a natural plantar medical material or/and an extractive in the pharmacy field, in particular to an application of herba elephantopi and an extractive in amedicament for treating pain diseases. The herba elephantopi and the extractive can be singly prepared into a pharmaceutical preparation as main active components or together with other components. The pharmaceutical preparation comprises various preparations in different administration routes, such as oral taking, injection, cavity taking, subcutaneous injection, and the like. The invention provides the new application of the herba elephantopi and the extractive for providing a new natural analgesic medicine and a new treatment idea for treating pain diseases. The invention is mainly used for the treatment of traumatic pain, chronic dull pain, stomach pain, cancer pain, neuralgia and dysmenorrheal and the comprehensive treatment of pain caused by other reasons. The prepared medicine hasno toxic and side effects, such as obvious addition, tolerance, and the like, is safe and natural for patients and has high efficiency.
Obesity and malnutrition affect many patients with osteoarthritis and can predispose patients to worse outcomes after total joint arthroplasty (TJA). However, these modifiable risk factors can be addressed in preoperative optimization programs driven by nurse navigators. Our aim is to provide resources and recommendations for nurse navigators when addressing obesity and malnutrition among TJA patients. In addition to discussions with nurse navigators regarding obesity and malnutrition, a literature review was conducted to assess the current practice standards for management. Nurse navigators often had difficulty implementing long-term interventions, but interventions in the literature included medical and bariatric treatments for obesity and more targeted assessment of nutrition status. These findings are incorporated into our recommendations for nurse navigators. Addressing obesity and malnutrition in preoperative optimization can contribute to improved outcomes, as has been demonstrated in current practice and in the literature.
PROBLEM TO BE SOLVED: To obtain a sheetlike pack cosmetic having excellent keratin ability to remove keratonic plugs and peelability. SOLUTION: This sheetlike pack cosmetic has a pack layer comprising a polyvinylpyrrolidone and a polyvinyl alcohol having >=80 mol.% degree of saponification in the ratio of 0.1-100 pts. wt. of the polyvinyl alcohol based on 100 pts. wt. of the polyvinylpyrrolidone.
Sitagliptin Tablets contain sitagliptin free base, an orally active inhibitor of the DPP-4 enzyme. 

Sitagliptin free base is described chemically as 7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazine.

The empirical formula is C16H15F6N5O and the molecular weight is 407.31. The structural formula is:

Sitagliptin free base is a white to off-white, non-hygroscopic powder. Sitagliptin free base is soluble in methanol and slightly soluble in water.

Each film coated tablet of sitagliptin contains sitagliptin free base 25 mg, 50 mg, or 100 mg as active ingredient and the following inactive ingredients: anhydrous dibasic calcium phosphate, colloidal silicon dioxide, croscarmellose sodium, malic acid, magnesium stearate, microcrystalline cellulose, and povidone. In addition, the film coating contains the following inactive ingredients: polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide. The 50 mg tablet's film coating also contains ferrosoferric oxide and iron oxide yellow. The 100 mg tablet's film coating also contains FD&C Yellow #6 Aluminum Lake and iron oxide yellow.
An aqueous wash composition has been found useful in methods for determination of specific binding ligands. The composition is buffered to a pH of less than or equal to 6 or greater than or equal to 9. It also includes as its essential component at least about 0.1 weight percent of an anionic surfactant which is represented by the formula: [A-SO3+y]-(1+y)[X+m]n wherein A is a hydrocarbon having a molecular weight of at least about 180, X+m is hydrogen or a monovalent or divalent cation, m is 1 or 2, is 0 or 1, and n is 1 or 2 provided that m and n are not both 2. Optionally and preferably, the wash composition also includes a nonimmunoreactive protein. This wash composition is particularly useful in methods for determination of microorganisms associated with periodontal diseases. Such methods can be of a variety of formats, but immunometric assays are particularly useful. The wash composition can be included as part of a diagnostic test kit.
Despite their general good health, an increasing proportion of elderly individuals require surgery due to an increase in average lifespan. However, because of their increased vulnerability, these patients need to be handled carefully to make sure that surgery does not cause more harm than good. Age-related postoperative cognitive disorders (POCD) and postoperative delirium (POD), two serious consequences that are marked by adverse neuropsychologic alterations after surgery, are particularly dangerous for the elderly. In the context of gynecologic procedures, POCD and POD are examined in this narrative review. The main question is how to limit the rates of POCD and POD in older women undergoing gynecologic procedures by maximizing the risk-benefit balance. Three crucial endpoints are considered: (1) surgical procedures to lower the rates of POCD and POD, (2) anesthetic techniques to lessen the occurrence and (3) the identification of individuals at high risk for post-surgery cognitive impairments. Risks associated with laparoscopic gynecologic procedures include the Trendelenburg posture and CO2 exposure during pneumoperitoneum, despite statistical similarities in POD and POCD frequency between laparoscopic and laparotomy techniques. Numerous risk factors are associated with surgical interventions, such as blood loss, length of operation, and position holding, all of which reduce the chance of complications when they are minimized. In order to emphasize the essential role that anesthesia and surgery play in patient care, anesthesiologists are vital in making sure that anesthesia is given as sparingly and quickly as feasible. In addition, people who are genetically predisposed to POCD may be more susceptible to the disorder. The significance of a thorough strategy combining surgical and anesthetic concerns is highlighted in this article, in order to maximize results for senior patients having gynecologic surgery.
PURPOSE: A pharmaceutical composition containing a therapeutically effective amount of radioactive arsenic-containing compounds and a pharmaceutically acceptable carrier is provided. The composition can be used in the treatment of tumors/cancers such as hematological malignancies and solid tumors selected from a group consisting of breast cancer, rectal cancer, liver tumor, ovarian cancer and prostate cancer. CONSTITUTION: The pharmaceutical composition contains a therapeutically effective amount of radioactive arsenic-containing compounds and a pharmaceutically acceptable carrier. The radioactive arsenic-containing compounds are prepared by the steps of: (i)subjecting an arsenic-containing compound to a neutron irradiation treatment to convert an arsenic element contained in an arsenic-containing compound to a radioactive arsenic isotope; and (ii)recovering the resultant product. The arsenic-containing compound is selected from a group consisting of As2O3, As2S3, AS2S2, and a combination thereof. The radioactive arsenic-containing compound is neutron-irradiated arsenic trioxide, and is formulated into an aqueous injection formulation. The pharmaceutical composition is administered parenterally, orally, or topically in an amount of 0.01 to 0.6 mg/Kg of body weight per day, in single or multiple doses.
NEW MATERIAL:A compound shown by the formula I (R is isopropyl, isobutyl, or sec-butyl). EXAMPLE:1, 2, 3, 4-Tetrahydro-2,4-dioxopyrimidin-5-carboxylic acid isopropyl ester. USE:An intermediate for a drug having strong multiplication inhibitory action on various tumor cells of mammals, life prolonging effects on leukemia and antiviral effects. PREPARATION:A carboxlic acid corresponding to a compound shown by the formula I is treated with a chlorinating agent in dimethylformamide (DMF) to give a corresponding carboxylic acid chloride-DMF.(1/2)HCl complex, which is reacted with a compound shown by the formula R-OH, to give a compound shown by the formula I. This compound is fluorinated in the presence of water, etc., to give a compound shown by the formula II (R1 is OH which may be optionally etheriifed) useful as the above-mentioned drug.
The invention discloses a skin-care product for preventing external stimulation by using radix pseudostellariae as a main component and a preparation method of the skin-care product. The skin-care product includes sun-screen, sunscreen day cream, moisturizing facial cleansing milk, whitening facial cleansing soap and perfume. The invention further provides a formula and preparation method of the skin-care product. Tests by the inventor discover and prove that the radix pseudostellariae extract has functions of moistening skin, protecting DNA and/or resisting inflammation, does not have cytotoxicity and is safe to use. Therefore, the radix pseudostellariae extract can be used for preparing skin-care products for preventing external stimulation by serving as the main component. The skin-care product for preventing external stimulation has an effect of improving the skin quality, and is capable of keeping skin moistened, improving skin elasticity, maintaining skin normal functions and preventing external stimulation.
The efficacy of Citalopram HBr Tablets as a treatment for depression was established in two placebo-controlled studies (of 4 to 6 weeks in duration) in adult outpatients (ages 18-66) meeting DSM-III or DSM-III-R criteria for major depression. Study 1, a 6-week trial in which patients received fixed Citalopram HBr Tablets doses of 10, 20, 40, and 60 mg/day, showed that Citalopram HBr Tablets at doses of 40 and 60 mg/day was effective as measured by the Hamilton Depression Rating Scale (HAMD) total score, the HAMD depressed mood item (Item 1), the Montgomery Asberg Depression Rating Scale, and the Clinical Global Impression (CGI) Severity scale. This study showed no clear effect of the 10 and 20 mg/day doses, and the 60 mg/day dose was not more effective than the 40 mg/day dose. In study 2, a 4-week, placebo-controlled trial in depressed patients, of whom 85% met criteria for melancholia, the initial dose was 20 mg/day, followed by titration to the maximum tolerated dose or a maximum dose of 80 mg/day. Patients treated with Citalopram HBr Tablets showed significantly greater improvement than placebo patients on the HAMD total score, HAMD item 1, and the CGI Severity score. In three additional placebo-controlled depression trials, the difference in response to treatment between patients receiving Citalopram HBr Tablets and patients receiving placebo was not statistically significant, possibly due to high spontaneous response rate, smaller sample size, or, in the case of one study, too low a dose.

In two long-term studies, depressed patients who had responded to Citalopram HBr Tablets during an initial 6 or 8 weeks of acute treatment (fixed doses of 20 or 40 mg/day in one study and flexible doses of 20-60 mg/day in the second study) were randomized to continuation of Citalopram HBr Tablets or to placebo. In both studies, patients receiving continued Citalopram HBr Tablet treatment experienced significantly lower relapse rates over the subsequent 6 months compared to those receiving placebo. In the fixed-dose study, the decreased rate of depression relapse was similar in patients receiving 20 or 40 mg/day of Citalopram HBr Tablets. Analyses of the relationship between treatment outcome and age, gender, and race did not suggest any differential responsiveness on the basis of these patient characteristics.

Comparison of Clinical Trial Results

Highly variable results have been seen in the clinical development of all antidepressant drugs. Furthermore, in those circumstances when the drugs have not been studied in the same controlled clinical trial(s), comparisons among the results of studies evaluating the effectiveness of different antidepressant drug products are inherently unreliable. Because conditions of testing (e.g., patient samples, investigators, doses of the treatments administered and compared, outcome measures, etc.) vary among trials, it is virtually impossible to distinguish a difference in drug effect from a difference due to one of the confounding factors just enumerated.
PURPOSE:A whitening cosmetic, obtained by incorporating isokojic acid having improved inhibitory action on melanization in a cosmetic base, capable of exhibiting improved whitening and antisuntan effect, and useful for skin cosmetic, e.g. safe toilet water, cream or milky lotion. CONSTITUTION:A whitening cosmetic obtained by incorporating water-soluble isokojic acid (=6-hydroxy-2-hydroxymethyl-1,4-pyrone) expressed by the formula in an amount of 0.01-10% in a usually used cosmetic base or assistant, etc. used in toilet water, milky lotion, pack, etc. The isokojic acid produced by cultivation of a microorganism or chemical synthetic product may be used as the above-mentioned isokojic acid. For example, in the case of tiolet water, a protectant, e.g. glycerol, and a skin nutriment, etc. are dissolved in purified water, an a preservative, perfume, etc. are dissolved in an alcohol. Both are then mixed and solubilized at room temperature to give the tiolet water. In the above- mentioned general production of the toilet water, 0.01-10% isokijic acid expressed by the formula is added to the water-soluble part to afford the aimed whitening toilet water.
Placebo: 2.4 mg/week SC in combination with TCOC treatment (i.e. diet/weight consultations).
Researches have proposed that obesity might contribute to development of oligoasthenospermia. This study was performed to confirm whether obesity contributes to oligoasthenospermia as well as the underlying mechanisms in mice fed with a high fat diet (HFD). Meanwhile, the actions of metformin, a drug of well-known weight-lowering effect, on sperm quality in obese mice were investigated. Our results showed that HFD feeding reduced sperm quality and steroid hormone levels in mice, associated with disruptions in testicular histomorphology and spermatogenesis. Moreover, obesity increased sperm apoptosis. These effects could be prevented by metformin treatment in HFD-fed mice. Mechanistically, an increasement in lipid contents associated with decreased hormone-sensitive lipase (HSL) protein expression in testes in HFD-fed mice was observed, which could be improved by metformin treatment. Then, the model of TM4 mouse Sertoli cells stimulated with palmitic acid (PA) was used to investigate the potential effect of lipid retention on testicular apoptosis and sperm quality reduction. In consistent, PA exposure elevated lipid contents as well as apoptosis in TM4 cells, which could also be improved by metformin treatment. Of note, the protein expression of HSL was reduced stimulated by PA in TM4 cells, also rescued by metformin. Then, anti-apoptosis effect of metformin would be lost with the deficiency of HSL. In summary, our study propose that obesity contributes to oligoasthenospermia by increasing sperm apoptosis induced by impaired lipid hydrolysis due to HSL down-regulation, which could be prevented with metformin treatment via regulating the expression of HSL in testis in mice.
Breathing is vital and must be concurrently robust and flexible. This rhythmic behavior is generated and maintained within a rostrocaudally aligned set of medullary nuclei called the ventral respiratory column (VRC). The rhythmic properties of individual VRC nuclei are well known, yet technical challenges have limited the interrogation of the entire VRC population simultaneously. Here we characterize over 15,000 medullary units using high-density electrophysiology, opto-tagging and histological reconstruction. Population dynamics analysis reveals consistent rotational trajectories through a low-dimensional neural manifold. These rotations are robust and maintained even during opioid-induced respiratory depression. During severe hypoxia-induced gasping, the low-dimensional dynamics of the VRC reconfigure from rotational to all-or-none, ballistic efforts. Thus, latent dynamics provide a unifying lens onto the activities of large, heterogeneous populations of neurons involved in the simple, yet vital, behavior of breathing, and well describe how these populations respond to a variety of perturbations.
Following informed consent, clinicians will be scheduled to participate in a 2 hour training on empathic communication with lung cancer patients. Surveys will be collected from 6 patients (3 pre-training, 3 post-training). Clinicians will complete one standardized patient assessment before training (pre-SPA) and one assessment after training (post-SPA). These are 12-minute video-recorded clinic consultations with standardized patients (trained actors).
Patients who meet the study selection criteria will be randomized into two groups in a 1:1 ratio: the usual care group and the intervention group. Initially, patients will be invited to participate in the study via a brief statement included in the patient result letter informing patients of their abnormal screening mammogram result. The patient navigator will then follow up with each patient who expresses interest in the study via telephone to reiterate the details of the project, answer any questions that the patients might have, and invite the patients to participate in the project if the patients meet the study inclusion criteria. Informed consent will be obtained from the study participants.

The primary role of the patient navigator will be to identify and address barriers to accessing timely diagnostic care. The patient navigator's duties will also include providing an array of services aimed at improving health care access and engagement, including appointment reminder phone calls, health education, assistance with scheduling appointments, providing information about available transportation options to the clinic sites (e.g., shuttle service provided by the institution), helping patients to connect with language interpretation services, providing assistance with resolving insurance issues, and motivating and coaching patients on the importance of timely follow-up of abnormal breast imaging results. The services provided by the patient navigator will be tailored to the specific needs of each patient and will be aimed at helping patients to overcome personal, cultural and systemic barriers to successfully completing follow-up.
Patients receive tazemetostat PO BID on days 1-28. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
40 septic shock patients requiring norepinephrine to maintain mean arterial pressure between 65 and 75 mmHg despite adequate volume resuscitation will be enrolled in the study. After an initial hemodynamic resuscitation aimed at achieve a mean arterial pressure between 65 and 75 mmHg and a mixed venous oxygen saturation (SvO2) ≥ 65%, patients will be randomly allocated to be treated with either a) intravenous administration of levosimendan 0.2 µg∙kg-1∙min-1 for 24 hrs, b)intravenous administration of dobutamine 5 µg∙kg-1∙min-1 for 36 hrs(control; each n = 20). At the end of the first 24 hrs of the study period, both groups will receive inhaled nitric oxide at the concentration of 35 ppm for further 12 hrs. In all patients norepinephrine was titrated to maintain mean arterial pressure between 65 and 75 mmHg. Data from right heart catheterization and sublingual microvascular network will be obtained just before randomization (baseline) and then after 24 and 36 hours.

The sublingual microvascular network will be studied using the sidestream dark field (SDF) imaging. The device will be applied on the lateral side of the tongue, in an area approximately 2-4 cm from the tip of the tongue. Sequences of 10 secs from eight adjacent areas will be recorded on disk using a personal computer. These sequences will be later analyzed by an investigator blinded to the patient's diagnosis and therapy.